**Name of journal: *World Journal of Translational Medicine***

**ESPS Manuscript NO: 22939**

**Manuscript Type: Original Article**

**Basic Study**

**Prednisolone inhibits SaOS2 osteosarcoma cell proliferation by activating inducible nitric oxide synthase**

Cazzaniga A *et al*. Prednisolone, nitric oxide and osteosarcoma cells

**Alessandra Cazzaniga, Jeanette AM Maier, Sara Castiglioni**

**Alessandra Cazzaniga, Jeanette AM Maier, Sara Castiglioni,** Dipartimento di Scienze Biomediche e Cliniche L. Sacco, Università di Milano, 20157 Milano, Italy

**Author contributions**: Castiglioni S, Cazzaniga A and Maier JA designed the research; Castiglioni S and Cazzaniga A performed the research and analyzed the data; Maier JA wrote the paper.

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of The Department of Biomedical and Clinical Sciences – University of Milan.

**Conflict-of-interest** **statement:** We declare no conflict of interest in the study design, its interpertation and presentation of its scientific content.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Dr. Jeanette AM Maier,** Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, Università di Milano, via GB Grassi 74, 20157 Milano, Italy.[jeanette.maier@unimi.it](mailto:jeanette.maier@unimi.it)

**Telephone**: +39-2-50319648

**Fax:** +39-2-50319659

**Received:** October 5, 2015

**Peer-review started:** October 5, 2015

**First decision:** November 24, 2015

**Revised:** December 14, 2015

**Accepted:** January 29, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM**: To investigate the effect of prednisolone, a synthetic [glucocorticoid](https://en.wikipedia.org/wiki/Glucocorticoid) used in inflammatory diseases, on the growth of cultured osteosarcoma cells.

**METHODS**: Two osteosarcoma cell lines with different degree of differentiation were used. SaOS2 show a rather mature phenotype, while U2OS are negative for almost all osteoblastic markers. The cells were exposed to different concentrations of prednisolone (1-9 µmol/L) with or without antioxidants or the inhibitor of inducible nitric oxide synthase L-NIL. Cell growth was assessed by counting viable cells. The production of nitric oxide was measured in the conditioned media by the Griess method. The production of reactive oxygen species was quantified using 2’-7’-dichlorofluorescein diacetate. Western blot with specific antibodies against nitric oxide synthases was performed on cell extracts.

**RESULTS**: Prednisolone inhibited SaOS2 cell growth in a dose dependent manner. No significant effects were observed in U2OS. The inhibition of SaOS2 growth is not due to oxidative stress, because antioxidants do not rescue cell proliferation. Since high concentrations of nitric oxide inhibit bone formation, we also measured nitric oxide and found it induced in SaOS2, but not in U2OS, exposed to prednisolone, because of the upregulation of inducible nitric oxide synthase as detected by western blot. Therefore, we treated SaOS2 with prednisolone in the presence or in the absence of L-NIL. L-NIL prevented NO release induced by prednisolone at all the concentrations apart from 9 µmol/L. At the same concentrations, we found that L-NIL rescued SaOS2 growth after exposure to prednisolone. In U2OS cells, prednisolone did not induce nitric oxide production nor affected cell growth. All together, these data indicate that a link exists between increased amounts of nitric oxide and growth inhibition in response to prednisolone in SaOS2.

**CONCLUSION**: Prednisolone inhibited SaOS2 proliferation by increasing the release of nitric oxide through the upregulation of inducible nitric oxide synthase, while no effect was exerted on U2OS.

**Key words**: Osteosarcoma cells; Prednisolone; Nitric oxide; Inos; eNOS; Reactive oxygen species

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:**  Since prednisolone, a widely used synthetic [glucocorticoid](https://en.wikipedia.org/wiki/Glucocorticoid), inhibits osteoblast proliferation, we evaluated its effects on osteosarcoma cells. In particular, we used two osteoblastic osteosarcoma cell lines with different degree of differentiation, *i.e.,* SaOS2, which have a rather mature phenotype, and U2OS, which are less differentiated. We found that prednisolone inhibited SaOS2 proliferation by increasing the release of nitric oxide through the upregulation of inducible nitric oxide synthase. Indeed, pharmacological inhibition with the iNOS inhibitor L-NIL restored the normal proliferation rate of the SaOS2. On the contrary, prednisolone did not modulate nitric oxide production nor cell growth in U2OS.

Cazzaniga A, Maier JA, Castiglioni S. Prednisolone inhibits SaOS2 osteosarcoma cell proliferation by activating inducible nitric oxide synthase. *World J Transl Med* 2016; In press

**INTRODUCTION**

Osteosarcomas are aggressive primary malignant tumors of the bone characterized by the deposition of immature bone by the neoplastic cells which most likely arise from mesenchymal stem cells. Osteosarcomas mostly affect teenagers and frequently metastasize. Nowadays, systemic multidrug chemotherapy and surgery are successful in 60% - 70% of patients. Therefore, novel approaches are foreseen.

Since glucocorticoids participate to the regulation of survival, differentiation, and proliferation of many cell types, including osteoblasts and bone mesenchymal stem cells[1-3], we asked whether glucocorticoids might control the growth of osteosarcoma cells. Glucocorticoids act by binding their cognate receptor which functions as a hormone-regulated transcription factor. In addition, glucocorticoids interact with transcription factors such as AP1 and NFκB and inhibit their activity. They can also modulate some intracellular signalling pathways, one of which is the MAP kinase cascade. Because of their effects on cell cycle progression and apoptosis[4], they are also used in the treatment of lymphoid malignancy and of some solid cancers[5,6].

In this study, we evaluate the effect of prednisolone, a synthetic [glucocorticoid](https://en.wikipedia.org/wiki/Glucocorticoid) widely used to treat inflammatory diseases, on cultured osteosarcoma cells. It is well known that cultured neoplastic cells have been the basis of cancer biology and the chase to identify drug treatments[7]. Two human osteosarcoma cell lines are particularly intriguing, *i.e.,* SaOS2 and U2OS, which are among the first generated cell lines used for anticancer research[8]. U2OS were derived from a moderately differentiated sarcoma of a 15-year-old girl, and SaOS2 from an osteogenic sarcoma of an 11-year-old girl. SaOS2 are relatively resistant to drugs because of the mutation of major oncosuppressors, *i.e.,* p53 and Rb[9], which are functional in U2OS. While SaOS2 show a mature phenotype, U2OS are negative for almost all osteoblastic markers but positive for cartilage markers like collagen II, IX and X and for type IV collagen, which is only expressed by very early differentiation stages but not by osteoblasts. These to cell lines were selected for this study because of their different degree of differentiation and gene expression.

**MATERIALS AND METHODS**

***Cell culture***

SaOS2 and U2OS (American Type Culture Collection) were cultured in DMEM containing 10% fetal bovine serum. Proliferation assays were performed on cells at low density (7000/cm2) with different concentrations of prednisolone. After trypsinization and staining with trypan blue solution (0.4%), the viable cells were counted. In some experiments cells were exposed to apocynin (10 μg/mL), trolox (40 μmol/L), or l-*N*6-(iminoethyl)-lysine-HCl (L-NIL) (100 μmol/L), a selective inhibitor of inducible nitric oxide synthase (iNOS).

***Reactive oxygen species evaluation***

Intracellular oxidative stress was quantified using 2’-7’-dichlorofluorescein diacetate (DCFH). Cells were seeded into black bottomed 96 plates (Greiner bio-one) and 24 h later exposed for 30 min to different concentrations of prednisolone dissolved in a 20 µmol/L DCFH solution. The rate of intracellular oxidative stress was evaluated by monitoring the emission at 529 nm of the DCFH dye using Promega Glomax Multi Detection System[10]. Data are shown as the mean of three independent experiments in triplicate ± SD. H2O2 (50 μmol/L) was used as a positive control.

***Nitric oxide synthase activity***

Nitric oxide synthase (NOS) activity was measured in the conditioned media by the Griess method as described[11]. Data are shown as the mean of four independent experiments in triplicate ± standard deviation.

***Western blot analysis***

Western blot was performed using anti- iNOS, total endothelial nitric oxide synthase (eNOS) and p-eNOSSer1177 antibodies (Cell Signalling) followed by incubation with secondary antibodieslabelled with horseradish peroxidase (GE Healthcare).Anti-actin antibodies (Sigma) were used to show that equal amounts of proteins were loaded per lane. The SuperSignal chemiluminescence kit (Pierce) was utilized to detectimmunoreactive proteins. Densitometry was performed using ImageJ software and results are shown as the mean ± SD of three separate experiments. A representative blot is shown.

***Statistical analysis***

Statistical significance was determined using the Student's T test and set at p values less than 0.05. In the figures a*P* < 0.05; b*P* ≤ 0.01; c*P* ≤ 0.001.

**RESULTS**

***Prednisolone inhibits SaOS2 cell proliferation***.

SaOS2 were cultured in media containing different concentrations of prednisolone and counted after 4 d. Figure 1A shows that prednisolone inhibits SaOS2 cell growth in a dose dependent manner. No effect is observed in cells treated with 1 µmol/L prednisolone, while growth inhibition is significant with 3, 6, and 9 µmol/L. Similar results were obtained when the MTT assay was used (data not shown). Under the same experimental conditions U2OS were less sensitive to prednisolone than SaOS2 since a modest growth inhibition was observed only with 9 µmol/L of prednisolone (Figure 1B).

We focused on SaOS2 to understand the mechanisms underlying the inhibitory effect of prednisolone. Since the detrimental effects of glucocorticoids in osteoblasts are mediated by the induction of oxidative stress[12], we measured intracellular reactive oxygen species (ROS) by DCF fluorescence in SaOS2. Prednisolone did not significantly affect the basal levels of DCF-detectable ROS (Figure 2A). Accordingly, antioxidants. *i.e.,* apocynin, a NADPH oxidase inhibitor, and trolox, a water soluble analog of α-tocopherol, did not prevent growth inhibition by prednisolone (Figure 2B).

***Prednisolone induces nitric oxide release in SaOS***

Because of the role of nitric oxide (NO) in bone homeostasis[13], we evaluated whether prednisolone affected NOS activity. After 24, 48 and 96 h of culture in various concentrations of prednisolone, we found that NOS activity was higher in SaOS2 treated with the glucocorticoid as detected by Griess assay (Figure 3A), while no increase of NO was detected in U2OS (Figure 3B). Since iNOS and eNOS were described in cultured osteoblast-like cells from various species[14], we evaluated the amounts of these enzymes by western blot in SaOS2. The phosphorylation of p-eNOSSer1177 was also investigated because it enhances enzyme activity[11]. After 12 and 24 h exposure to prednisolone (6 µmol/L), iNOS was up-regulated (Figure 3C), while the amounts of total eNOS and p-eNOSSer1177remained almost unvaried.

***Inhibition of iNOS activity rescues SaOS2 cell proliferation.***

To study whether an increased activity of NOS was responsible for SaOS2 growth retardation by prednisolone, the cells were cultured in medium containing various concentrations of prednisolone in the presence or in the absence of the iNOS inhibitor L-NIL (100 μmol/L) for 96 h. Figure 4A shows that L-NIL (100 μmol/L) prevented NO release induced by prednisolone up to 6 µmol/L, but not at 9 µmol/L. We then counted the cells and found that L-NIL prevents prednisolone-dependent growth inhibition up to 6 µmol/L (Figure 4B).

**DISCUSSION**

High levels of glucocorticoids impact on the generation and lifespan of osteoblasts[15]. In humans, prednisolone, even at low doses[16] , causes significant bone loss and increases the risk of fractures through a direct action mainly on osteoblasts and osteocytes[17]. Because of the inhibitory effect of prednisolone on osteoblast proliferation and viability, we asked whether prednisolone might inhibit also osteosarcoma cell proliferation. Indeed, the outcome of antineoplastic therapies in osteosarcoma is not satisfactory and the quest for novel treatments continues. Here, we investigated the effects of prednisolone on two human osteoblastic osteosarcoma cell lines that reveal different a degree of differentiation, *i.e.,* SaOS2 and U2OS[8]. We found that SaOS2 are growth inhibited by prednisolone while U2OS are not. We therefore investigated the mechanisms underlying prednisolone inhibition of SaOS2 cell growth, which also means to understand why U2OS are far less sensitive to the drug. Glucocorticoids are known to alter redox balance. Indeed, the administration of prednisolone to mice increased ROS production in the bone and dexamethasone had similar effects on osteoblastic cells *in vitro*[12]. Moreover, prednisolone enhanced the formation of superoxide by augmenting NADPH oxidase activity in pulmonary endothelial cells[18]. We found no significant induction of ROS production in prednisolone-treated SaOS2. In agreement with this result, two anti-oxidants with different mechanisms of action have no effect in preventing SaOS2 cell growth inhibition by prednisolone.

Also NO has a role in bone homeostasis. Low NO levels stimulate, while high concentrations inhibit bone formation. It is eNOS, constitutively expressed in the bone, that is implicated in maintaining the basal levels of NO[19]. Accordingly, eNOS-/- mice show defective bone formation and are osteopenic[11]. Also iNOS null mice show imbalances in bone osteogenesis and abnormalities in bone healing[11]. It is interesting to note that iNOS pathway is crucial in bone resorption upon inflammatory stimuli and also mediates the negativeeffects of estrogen depletion on bones[20]. Indeed, once activated, iNOS is capable of generating high levels of NO locally for many hours. It should be recalled that NO is also an inducer of stress signaling, owing to its ability to damage proteins and DNA. We here show that SaOS2 exposed to prednisolone upregulate iNOS and, because of this, produce higher amounts of NO than untreated cells. Indeed, pharmacological inhibition of iNOS reduced NO release to basal levels and restored the normal proliferation rate of the cells treated with prednisolone. The mechanisms implicated in iNOS induction are still a matter of investigation. It is known that iNOS is regulated through the activation of several signaling pathways among which NFkB and MAPK. We can rule out a role of NFkB, since glucocorticoids suppress NFkB activity. More studies are necessary to reveal the pathways responsible for the increase of iNOS activity.

It is noteworthy that prednisolone does not induce NO in U2OS and this might account for the different behavior of the two cell lines. It is noteworthy that NO impairs also U2OS proliferation as shown in a study that links the increased activity of iNOS and the detrimental effects of benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC) on these cells[21]. It is also possible that the different response of SaOS2 and U2OS to prednisolone is due to the many differences of their proteomic profile[9,22]. Alternatively, since the glucocorticoid receptor gene generates several splice and translation protein variants that lead to different genomic and non genomic effects, the different response of U2OS and SaOS2 might result from the expression of various isoforms of glucocorticoid receptors.

We have previously shown that increased iNOS activity mediates SaOS2 growth inhibition by low magnesium[11]. Therefore NO is emerging as a relevant signaling molecule to control SaOS2 cell proliferation.

Our results indicate that prednisolone impairs SaOS2 cell proliferation through the upregulation of iNOS and consequent induction of NO release.

**COMMENTS**

***Background***

Glucocorticoids control the growth and differentiation of osteoblasts and bone mesenchymal stem cells. Little is known about the effects of glucocorticoids on osteosarcoma cells. We therefore evaluated the response to prednisolone of two human osteosarcoma cell lines, *i.e.,* SaOS2, which show a mature phenotype, and U2OS, which are rather undifferentiated.

***Research frontiers***

Prednisolone inhibited SaOS2 cell growth through the induction of inducible nitric oxide synthase with consequent increase of nitric oxide production. No effects were observed in U2OS.

***Innovations and breakthroughs***

Nitric oxide is emerging as a relevant signaling molecule to control SaOS2 cell proliferation under different experimental conditions. This result also highlights the different sensitivity to prednisolone of osteosarcoma cells with different degree of differentiation.

***Applications***

More than one cell line should be used when in vitro experiments are performed to test the response to various compounds. The possibility of using glucocorticoids in animal models of osteosarcoma should be fostered.

***Peer-review***

The manuscript by Cazzaniga *et al* analyses the effects of prednisolone on two different osteosarcoma cell lines. The data are novel and the experiments have been competently performed.

**REFERENCES**

1 **Li H**, Li T, Fan J, Li T, Fan L, Wang S, Weng X, Han Q, Zhao RC. miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. *Cell Death Differ* 2015; **22**: 1935-1945 [PMID: 26206089 DOI: 10.1038/cdd.2015.99]

2 **Li T**, Li H, Li T, Fan J, Zhao RC, Weng X. MicroRNA expression profile of dexamethasone-induced human bone marrow-derived mesenchymal stem cells during osteogenic differentiation. *J Cell Biochem* 2014; **115**: 1683-1691 [PMID: 24802236 DOI: 10.1002/jcb.24831]

3 **Canalis E**, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int* 2007; **18**: 1319-1328 [PMID: 17566815 DOI: 10.1007/s00198-007-0394-0]

4 **Schlossmacher G**, Stevens A, White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. *J Endocrinol* 2011; **211**: 17-25 [PMID: 21602312 DOI: 10.1530/JOE-11-0135]

5 **Pirotte B**, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. *J Neurooncol* 1997; **32**: 63-69 [PMID: 9049864 DOI: 10.1023/A:1005733416571]

6 **Sionov RV**, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. *Adv Cancer Res* 2008; **101**: 127-248 [PMID: 19055945 DOI: 10.1016/S0065-230X(08)00406-5]

7 **Borrell B**. How accurate are cancer cell lines? *Nature* 2010; **463**: 858 [PMID: 20164888 DOI: 10.1038/463858a]

8 **Pautke C**, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, Milz S. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. *Anticancer Res* 2004; **24**: 3743-3748 [PMID: 15736406]

9 **Niforou KM**, Anagnostopoulos AK, Vougas K, Kittas C, Gorgoulis VG, Tsangaris GT. The proteome profile of the human osteosarcoma SaOS2 cell line. *Cancer Genom Proteom* 2006; **3:** 325-346

10 **Castiglioni S**, Caspani C, Cazzaniga A, Maier JA. Short- and long-term effects of silver nanoparticles on human microvascular endothelial cells. *World J Biol Chem* 2014; **5**: 457-464 [PMID: 25426268 DOI: 10.4331/wjbc.v5.i4.457]

11 **Leidi M**, Dellera F, Mariotti M, Banfi G, Crapanzano C, Albisetti W, Maier JA. Nitric oxide mediates low magnesium inhibition of osteoblast-like cell proliferation. *J Nutr Biochem* 2012; **23**: 1224-1229 [PMID: 22209000 DOI: 10.1016/j.jnutbio.2011.06.016]

12 **Almeida M**, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts. *J Biol Chem* 2011; **286**: 44326-44335 [PMID: 22030390 DOI: 10.1074/jbc.M111.283481]

13 **Wimalawansa SJ**. Nitric oxide and bone. *Ann N Y Acad Sci* 2010; **1192**: 391-403 [PMID: 20392265 DOI: 10.1111/j.1749-6632.2009.05230]

14 **MacPherson H**, Noble BS, Ralston SH. Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells. *Bone* 1999; **24**: 179-185 [PMID: 10071909 DOI: 10.1016/S8756-3282(98)00173-2]

15 **Weinstein RS**, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. *J Clin Invest* 1998; **102**: 274-282 [PMID: 9664068 DOI: 10.1172/JCI2799]

16 **Ton FN**, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. *J Bone Miner Res* 2005; **20**: 464-470 [PMID: 15746991 DOI: 10.1359/JBMR.041125]

17 **Henneicke H**, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ. Glucocorticoids and bone: local effects and systemic implications. *Trends Endocrinol Metab* 2014; **25**: 197-211 [PMID: 24418120 DOI: 10.1016/j.tem.2013.12.006]

18 **Muzaffar S**, Shukla N, Angelini GD, Jeremy JY. Prednisolone augments superoxide formation in porcine pulmonary artery endothelial cells through differential effects on the expression of nitric oxide synthase and NADPH oxidase. *Br J Pharmacol* 2005; **145**: 688-697 [PMID: 15852033 DOI: 10.1038/sj.bjp.0706235]


19 **Klein-Nulend J**, van Oers RF, Bakker AD, Bacabac RG. Nitric oxide signaling in mechanical adaptation of bone. *Osteoporos Int* 2014; **25**: 1427-1437 [PMID: 24322479 DOI: 10.1007/s00198-013-2590-4]

20 **van Bezooijen RL**, Van der Bent C, Papapoulos SE, Löwik CW. Oestrogenic compounds modulate cytokine-induced nitric oxide production in mouse osteoblast-like cells. *J Pharm Pharmacol* 1999; **51**: 1409-1414 [PMID: 10678496 DOI: 10.1211/0022357991777047]


21 **Wu CL**, Huang AC, Yang JS, Liao CL, Lu HF, Chou ST, Ma CY, Hsia TC, Ko YC, Chung JG. Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of caspase-3, mitochondria dysfunction and nitric oxide (NO) in human osteogenic sarcoma U-2 OS cells. *J Orthop Res* 2011; **29**: 1199-1209 [PMID: 21374707 DOI: 10.1002/jor.21350]

22 **Niforou KM**, Anagnostopoulos AK, Vougas K, Kittas C, Gorgoulis VG, Tsangaris GT. The proteome profile of the human osteosarcoma U2OS cell line. *Cancer Genomics Proteomics* 2008; **5**: 63-78 [PMID: 18359981]


**P-Reviewer:** **Angoules A,** Guerado E, Lawen A **S-Editor:** Qi Y **L-Editor: E-Editor:**




**Figure 1 Prednisolone inhibits the growth of SaOS2 but not of U2OS.** A: Viable SaOS2 cells were counted after 4 d in the presence of different concentrations of prednisolone (a*P* < 0.05; b*P* < 0.01);B:Viable U2OS cells treated as above and counted after 96 h (a*P* < 0.05).Results are shown as the mean of three separate experiments ± standard deviation. CTR: control.



**Figure 2** **Prednisolone does not induce the formation of reactive oxygen species and antioxidants do not prevent growth inhibition.** A: SaOS2 cells were treated with various concentrations of prednisolone. H2O2 was used as positive control. ROS generation was measured. Data are shown as the mean of three separate experiments ± SD. *P* value was calculated *vs* untreated cells and found not significant. CTR: Control.B: SaOS2 cells were treated with apocynin (10 µg/mL) or trolox (40 µmol/L in the presence of prednisolone (Prd). Viable cells were counted after 96 h. Results are shown as the mean of three separate experiments ± SD.



**Figure 3 Prednisolone increases the release of nitric oxide in SaOS2.** A:SaOS2 were cultured in the presence of different concentrations of prednisolone. NO was measured after 24, 48 and 96 hours. Results are expressed as the mean ± SD of four different experiments (a*P* < 0.05, b*P* < 0.01, c*P* < 0.001). B:U2OS cells were processed as described in (A). No statistical significance was achieved.C:SaOS2 cells exposed to prednisolone for 12 and 24 h and then lysed. 80 µg of protein extracts were loaded on SDS-PAGE. Western blots using specific antibodies against iNOS, eNOS, p-eNOS-P-Ser1177 were performed. Actin shows that equal amounts of protein were loaded per lane. The figure shows a representative blot. D: The histogram shows the quantitative evaluation of NOS/actin ratio by densitometry. Results are expressed as the mean ± standard deviation of three separate experiments (b*P* < 0.01).



**Figure 4 Pharmacological inhibition of iNOS rescues SaOS2 cell growth.** A:SaOS2 were treated with prednisolone in the presence or in the absence of L-NIL (100 μmol/L). NO was measured as described (b*P* < 0.01); B: Viable SaOS2 cells were counted after 4 d in the presence of different concentrations of prednisolone with or without L-NIL (b*P* < 0.01).